A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-D4010 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs SUVN D4010 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions
- Sponsors Suven Life Sciences
- 03 Jun 2016 Status changed from recruiting to completed.
- 19 Oct 2015 Results presented at the annual meeting of the Society for Neuroscience (SFN) 2015, as per Suven Life Science media release.
- 02 Sep 2015 According to a Suven Life Sciences media release, status changed from planning to recruiting.